Recombinant Human CD69 Protein, CF
R&D Systems, part of Bio-Techne | Catalog # 8468-CD
Key Product Details
Source
NS0
Accession #
Structure / Form
Disulfide-linked homodimer
Conjugate
Unconjugated
Applications
Bioactivity
Product Specifications
Source
Mouse myeloma cell line, NS0-derived human CD69 protein
Gly64-Lys199 with an N-terminal 9-His tag
Gly64-Lys199 with an N-terminal 9-His tag
Purity
>95%, by SDS-PAGE with silver staining.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
N-terminal Sequence Analysis
His
Predicted Molecular Mass
17 kDa
SDS-PAGE
20-30 kDa, reducing conditions
Activity
Measured by its binding ability in a functional ELISA.
When Recombinant Human CD69 is coated at 5 µg/mL (100 µL/well), the concentration of Recombinant Human Galectin-1 (Catalog # 1152-GA) that produces a 50% optimal binding response is 0.4-2 µg/mL.
When Recombinant Human CD69 is coated at 5 µg/mL (100 µL/well), the concentration of Recombinant Human Galectin-1 (Catalog # 1152-GA) that produces a 50% optimal binding response is 0.4-2 µg/mL.
Scientific Data Images for Recombinant Human CD69 Protein, CF
Recombinant Human CD69 Protein Binding Activity
When Recombinant Human CD69 is coated at 5 µg/mL (100 µL/well), the concentration of Recombinant Human Galectin-1 Recombinant Human Galectin-1 (Catalog # 1152-GA) that produces a 50% optimal binding response is 0.4-2 µg/mL.Recombinant Human CD69 Protein SDS-PAGE
1 μg/lane of Recombinant Human CD69 was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by silver staining, showing R bands at 22.0, 27.9 kDa and NR bands at 39.3, 42.1, 47.2 kDa.Formulation, Preparation and Storage
8468-CD
Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
Reconstitution |
Reconstitute at 250 μg/mL in PBS.
|
Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: CD69
References
- Gonzalez-Amaro, R. et al. (2013) Trends Mol. Med. 19:625.
- Ziegler, S.F. et al. (1993) Eur. J. Immunol. 23:1643.
- Hamann, J. et al. (1993) J. Immunol. 150:4920.
- Lopez-Cabrera, M. et al. (1993) J. Exp. Med. 178:537.
- Bieber, T. et al. (1992) J. Invest. Dermatol. 98:771.
- Alari-Pahissa, E. et al. (2012) J. Leukoc. Biol. 92:145.
- Lamana, A. et al. (2011) J. Invest. Dermatol. 131:1503.
- Radulovic, K. et al. (2012) J. Immunol. 188:2001.
- Shinoda, K. et al. (2012) Proc. Natl. Acad. Sci. USA 109:7409.
- Radulovic, K. et al. (2013) PLoS ONE 8:e65413.
- Hasegawa, A. et al. (2013) PLoS ONE 8:e65494.
- Shiow, L.R. et al. (2006) Nature 440:540.
- Martin, P. et al. (2010) J. Allergy Clin. Immunol. 126:355.
- Martin, P. et al. (2010) Mol. Cell. Biol. 30:4877.
- de la Fuente, H. et al. (2014) Mol. Cell. Biol. 34:2479.
- Cruz-Adalia, A. et al. (2010) Circulation 122:1396.
- Miki-Hosokawa, T. et al. (2009) J. Immunol. 183:8203.
Alternate Names
CD69, EA-1, Leu23, MLR-3, p60
Gene Symbol
CD69
UniProt
Additional CD69 Products
Product Documents for Recombinant Human CD69 Protein, CF
Product Specific Notices for Recombinant Human CD69 Protein, CF
For research use only
Loading...
Loading...
Loading...
Loading...